Showing results (1-10 of 127) with videos related to
Sort By:
Pageof 13
Discovery Medicine|January 20, 2007
Targeting the messengers of death: the advent of selective activation of apoptosis for cancer therapyEdwin Bremer, Wijnand HelfrichMethods in Molecular Biology (Clifton, N.J.)|February 6, 2014
Bifunctional antibody fragment-based fusion proteins for the targeted elimination of pathogenic T-cell subsetsWijnand Helfrich, Edwin BremerFrontiers in Bioscience : a Journal and Virtual Library|May 30, 2008
EpCAM-targeted induction of apoptosisEdwin Bremer, Wijnand HelfrichMethods in Molecular Biology (Clifton, N.J.)|November 23, 2018
Development of Bispecific Antibody Derivatives for Cancer ImmunotherapyYuan He, Wijnand Helfrich, Edwin BremerCancer Letters|January 11, 2011
Antibody-based fusion proteins to target death receptors in cancerMarco de Bruyn, Edwin Bremer, Wijnand HelfrichMedicinal Research Reviews|July 28, 2011
Therapeutic potential of Galectin-9 in human diseaseValerie R Wiersma, Marco de Bruyn, Wijnand Helfrich, et al.The Journal of Gene Medicine|August 5, 2014
Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL)Mohammad Arabpour, Klaas Poelstra, Wijnand Helfrich, et al.Frontiers in Oncology|March 10, 2015
The ever-expanding immunomodulatory role of calreticulin in cancer immunityMarco de Bruyn, Valerie R Wiersma, Wijnand Helfrich, et al.BMC Gastroenterology|May 7, 2010
Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in ratsYunwei Wei, Ping Chen, Marco de Bruyn, et al.International Journal of Cancer|January 30, 2004
Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2Edwin Bremer, Jos Kuijlen, Douwe Samplonius, et al.Pageof 13